Is Kiniksa Pharmaceuticals International Plc overvalued or undervalued?

As of 11 August 2025, the valuation grade for Kiniksa Pharmaceuticals International Plc moved from fair to attractive, indicating a positive shift in its perceived value. The company appears to be undervalued, particularly when considering its P/E ratio of 565.79, which is significantly higher than the industry average, and an EV to EBITDA ratio of 402.35. Additionally, the absence of a PEG ratio suggests that traditional growth metrics may not apply, further complicating the valuation landscape. In comparison to its peers, Kiniksa's high P/E ratio stands out, with no direct peer provided for a more comprehensive analysis. The recent stock performance shows that Kiniksa has outperformed the S&P 500 year-to-date with a return of 81.60% compared to the index's 12.22%, reinforcing the notion that the stock is gaining traction in the market despite its high valuation ratios.